About Indivior
Indivior is a company based in Richmond Hill (United States) founded in 2014. The company has 1,050 employees as of December 31, 2024. Indivior has completed 1 acquisition, including Opiant Pharmaceuticals. Indivior offers products and services including Addiction Recovery Treatments. Indivior operates in a competitive market with competitors including Ethypharm, Braeburn, Cessation Therapeutics, Amygdala Neurosciences and Aelis Farma, among others.
- Headquarter Richmond Hill, United States
- Employees 1050 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Indivior Plc
-
Annual Revenue
$1.19 B (USD)8.69as on Dec 31, 2024
-
Net Profit
$2 M (USD)0as on Dec 31, 2024
-
EBITDA
$314 M (USD)26.1as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
NIH
& 1 more
-
Employee Count
1050
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Indivior
Indivior is a publicly listed company on the NASDAQ with ticker symbol INDV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Indivior
Indivior offers a comprehensive portfolio of products and services, including Addiction Recovery Treatments.
Medications aimed at supporting recovery from addiction and behavioral issues
People of Indivior
Unlock access to complete
Unlock access to complete
Leadership Team
75 people
Sales and Marketing
28 people
Senior Team
22 people
Clinical Team
17 people
Finance and Accounting
15 people
Operations Team
12 people
Software Development Team
12 people
Head Team
11 people
Unlock access to complete
Funding Insights of Indivior
Investors in Indivior
Indivior has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Indivior
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Indivior
Indivior has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Opiant Pharmaceuticals.
Investment portfolio details for Indivior
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for addictive and eating disorders are developed.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Indivior
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Indivior
Detailed financials for Indivior
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Indivior Comparisons
Peer comparison for Indivior
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Indivior
Indivior operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ethypharm, Braeburn, Cessation Therapeutics, Amygdala Neurosciences and Aelis Farma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Long-acting therapies for opioid addiction and chronic pain are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapy based vaccines to manage addictions
|
|
| Locked | Locked | Locked |
Therapies for substance use disorders are developed by Amygdala Neurosciences.
|
|
| Locked | Locked | Locked |
Developer of small molecule drugs targeting CB1 receptor for CNS diseases
|
Detailed competitors of Indivior
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Indivior
Complete news archive for Indivior
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Indivior
Indivior was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Indivior is headquartered in Richmond Hill, United States. It is registered at Richmond Hill, Georgia, United States.
As of Dec 31, 2024, the latest employee count at Indivior is 1,050.
Annual revenue of Indivior is $1.19B as on Dec 31, 2024.
Indivior was founded in 2014 and is headquartered in Richmond Hill, United States. Operations focus on the pharmaceutical sector, where drugs for addiction treatment are developed and commercialized. The portfolio consists of buprenorphine formulations, including sublingual films, tablets, and combinations with naloxone, all indicated for opioid substance abuse management. Activities span research, development, and market distribution in this specialized therapeutic area.
Indivior's top competitors include Ethypharm, Amygdala Neurosciences and Aelis Farma.
Indivior offers Addiction Recovery Treatments.
Yes, Indivior is publicly traded on NASDAQ under the ticker symbol INDV.
Indivior has made 1 acquisition, including Opiant Pharmaceuticals.
Indivior has 2 investors. Key investors include NIH, and Athyrium Capital Management.
The ticker symbol of Indivior is INDV on NASDAQ.